04/12/2007 07:52 PAX 5105741473

PDL BIOPHARMA

RECEIVED CENTRAL FAX CENTER **6**002

APR 1 2 2007

RECEIVED

APK 1 2 ZUU/
CENTRAL FAX CENTER
PTO/S8/82 (01-08)
Approved for use through 12/31/2003, OMB 08:9-0033
U.B. Patent and Treatment Office, U.S. DEPARTMENT OF COMMERCEMAY U 4 2007
Under the Preparation Act of 1995, no persons are required to respond to a cohootion of information united in the property of the control number.

Application Number Filing Date AUGUST 18, 2000 REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY First Named Inventor DEVID MACK of al. Art Unit 1634 AND Examiner Name DIBNA B. JOHANNSEN CHANGE OF CORRESPONDENCE ADDRESS Attorney Docket Number 155 US CP02

			~ 	
i hereby revoke all previ	ous powers of attorney plyen in	the above-Ideni	ified application,	
A Power of Attorney is submitted herewith.				
OR			· · · · · · · · · · · · · · · · · · ·	
I hereby appoint the	a practitioners associated with the	Customer Numb	47470	
Please change the correspondence address for the above-identified application to:				
The address as Customer Number		47470		,
OR			··	
Firm or Individual Name				
Address			•	
City		State	Zlp	
Country		· · · · · · · · · · · · · · · · · · ·		
Telephone		Emall	•	
I am the:				
Applicant/Inventor.				
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is analosed. (Form PTO/SB/96)				
SIGNATURE of Applicant or Assignee of Record				
Signature Co. Social				
Name Cynilla L Shumato - Vice President, Logal Affairs				
Date	911,7007	Telephone	510-574-1400	
NOTE: Signatures of all the treoritors or estalgrees of record of the outro troorest or their representative(s) are required. Submit multiple forms if more than one or signature is required, see below.				
✓ Total of 1				
			anni in the maile which is to file	faret by ING USPTO

This collection of intermetha is required by 37 CFR 13-6. The Information is required to obtain or retain a benefit by the public which is to fit (and by the USPTO to process) as application. Confidentially is governed by 38 U.S.O. 122 and 37 CFR 1,14 and 1,14. This collection is asternating that the same to complete including gathering, prepeting, and submidding the completed explication form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Page 14-5. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BEND TO: Commissioner for Patunts, P.O. BOX 14-60, Albertating, VA 22313-14-50.

if you need assistance in completing the form, cell 1-800-PTD-9199 and select option 2.

PAGE 2/3 * RCVD AT 4/12/2007 10:52:00 AM [Castern Daylight Time] * SVR:UCPTO-EFXRF-3/1 * DNR; 27/38300 * CSID:5105741473 * DURATION (mm-48):01-34

6762020

04/12/2007 07:52 FAX 5105741473

PDL BIOPHARMA

RECEIVED CENTRAL FAX CENTER

2000

MAY U 4 2007

PTC/88/96 (98-96)
Approved for use through 93/31/2007, CMB 9861-9331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COVMERCE

	STATEMENT UNDER 37 CFR 3.73(b)			
Applicant/Patent Owner: PDL BioPr	erros, Inc.			
Application No./Patent No.: _09/642	.034 - 6.762.020 Filed/leaue Date: <u>08/18/00 - 07/13/04</u>			
Entitled: METHODS OF DIAGNOSIS OF BREAST CANCER				
POL RioPharma, Inc. (Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)			
states that it is: 1, the assignee of the entire rigi	nt, title, and interest; or			
2. The extent (by percentage) of	entire right, title and interest of its ownership interest is%)			
In the patent application/patent iden	dified above by virtue of either:			
A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy. thereof is attached.				
OR B. A chain of title from the invent	or(s), of the petent application/pirtent identified above, to the current assignce as follows:			
1. From: Inventore	To: EOS Elatechnology, Inc.			
The document was recorded in the United States Patent and Trademark Office at				
•	me_0284 or for which a copy thereof is attached.			
2. From: <u>EOS Blotechnolom</u>				
Roof a17486	zordod in the United States Patent and Trademark Office at, or for which a copy thereof is attached.			
3. From: Protein Design Lab The document was rec	n, Inc. To: POL BioPhanne, Inc.			
Reul _017480	Frame _0242 or for which a copy thereof is attached.			
Additional documents in the	e chain of title are listed on a supplemental sheet.			
As required by 37 CFR 3.73(b) appligness was, or concurrently is be	(1)(i), the documentary evidence of the chain of title from the original owner to the ing. submitted for recordation pursuant to 37 CFR 3.11,			
[NOTE: A separate copy (/.e., o Division in accordance with 302.08]	true copy of the original assignment document(s)) must be submitted to Assignment in 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP			
The undersigned (whese title is eup	Signature Date			
	ynthia L. Strumete 510.574.1400			
Print	od or Typed Name Telephone Number			
Yico F	resident Legal Affalm			

This collection of information is required by \$7 CFR 3.73(5). The information is required to obtain or rotain a buneris by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 30 U.S.C. 122 and 37 CFR 1.11 and 1.14. This oblication is estimated to take 12 individues to complete, including patheting, prepeting, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, any comments on the amount of time you require to complete this form and/or supported by formating this powers, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, cell 1-800-PTO-9199 and select option 2.

PAGE 3/3 " RCVD AT 4/12/2007 10:32:00 AM [Eastern Doylight Time] " SVR:USPTO-EFXRP-3/1 " DNIS:2738300 " CBID:0105741473 " DURATION (min-ss):01-34